CTLA4

[Science Translational Medicine] Ex vivo treatment of mouse and human dendritic cells promoted their IFN1-dependent activation, and vaccination studies in mice demonstrated stimulation of antigen cross-presentation and T cell priming in vivo.

[Scientific Reports] The authors reported a phenotypic screening of a human secretome library in human Treg cells utilising a high throughput flow cytometry technology.

[Fate Therapeutics, Inc.] Fate Therapeutics, Inc. announced that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. FT819 is the first-ever CAR T-cell therapy derived from a clonal master iPSC line.

[Transgene] Transgene and BioInvent International AB announce that their Investigational New Drug application for BT-001 has been granted by the US FDA. This IND will allow patients in the US to be enrolled into the ongoing Phase I/IIa clinical trial of this novel oncolytic virus BT-001.

[Proceedings of the National Academy of Sciences of the United States of America] Scientists showed that elevated levels of Delta-like 1 (DLL1) in the breast and lung tumor microenvironment induced long-term tumor vascular normalization to alleviate tumor hypoxia and promoted the accumulation of interferon γ–expressing CD8+ T cells and the polarization of M1-like macrophages.

[European Journal of Immunology] High levels of FOXP3, CTLA4 and CD25 expression, demethylation of the FOXP3 promoter and high suppressive ability were found with no differences between Tregs and RA+Tregs.